ArticleAnalytical chemistry2025
High-Frequency Microfluidic Fractionation for Compound-Resolved Bioactivity-Based Metabolomics.
Article in Analytical chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolomics-Based Identification of α-Glucosidase Inhibitors fromMolecules (Basel, Switzerland) · 2026Article
- Proteotoxic Stress Bioreporter Enables Mechanism-Informed Antibiotic Discovery.Journal of natural products · 2026Article
- A Functional Metabolomics Framework to Track Microbiome Drug Metabolism.bioRxiv : the preprint server for biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Specialized metabolites represent a prolific source of potential drug candidates. However, the process from detecting bioactivity in a crude metabolite extract to unambiguously identifying the active agent is a tedious and expensive endeavor. Speeding up this procedure is crucial, as new drugs, such as antibiotics, are urgently needed. Furthermore, the systematic functional assessment of complex metabolome samples represents a key bottleneck in nontargeted metabolomics, which once solved, holds the potential to fundamentally advance our systematic understanding of biology. To tackle this central bioanalytical challenge, we developed a compound-resolved bioactivity-based metabolomics workflow that combines nontargeted liquid chromatography tandem mass spectrometry (LC-MS/MS), high frequency fractionation on microfluidic devices and subsequent readout with luminescent bioreporter strains. Central for this workflow is a custom high-speed (∼1 Hz frequency) fractionation device that spots the mobile phase onto a microfluidic paper-analytical device (μPAD) in parallel to MS/MS data acquisition. Subsequently, the μPAD can be overlaid with a bioreporter strain, which displays cellular stress by expressing luciferase. The luminescence signal can then be correlated to MS signals through their chromatographic profiles. We evaluated five different luciferase-expressing bioreporter strains which provide information about different antibacterial modes of action, and tested the workflow with different antibiotic standards and mixtures thereof, as well as crude extracts from the known antibiotic producer
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.